These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1149754)

  • 41. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 42. Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor.
    Hökendorf H
    J Int Med Res; 1979; 7(1):19-28. PubMed ID: 421963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 45. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 48. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gout induced by L-dopa and decarboxylase inhibitors.
    Calne DB; Fermaglich J
    Postgrad Med J; 1976 Apr; 52(606):232-3. PubMed ID: 1273018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 51. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
    Namba S; Ishimitsu H; Nakasone S
    No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
    [No Abstract]   [Full Text] [Related]  

  • 53. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
    Albani C; Buck A
    Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
    [No Abstract]   [Full Text] [Related]  

  • 54. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):227-34. PubMed ID: 8369102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
    Vartanian KZ
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(12):1777-81. PubMed ID: 6803476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J ; Constantinidis J; Dick P; Yanniotis G; Tissot R
    Schweiz Med Wochenschr; 1975 Jan; 105(4):121-4. PubMed ID: 1124379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
    Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
    Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.